USFDA concludes inspection at Solara's Cuddalore facility with Zero 483 inspectional observations

KIMS posts Q1 FY24 consolidated PAT at Rs. 80.81 Cr

KIMS has reported total income of Rs. 609.14 crores during the period ended June 30, 2023

Torrent Pharmaceuticals posts Q1 FY 24 consolidated PAT at Rs. 378 Cr

Torrent Pharmaceuticals has reported total income of Rs. 2625 crores during the period ended June 30, 2023

Gland Pharma posts Q1 FY24 consolidated PAT at Rs. 194.10 Cr

Gland Pharma has reported total income of Rs. 1246.23 crores during the period ended June 30, 2023

Tatva Chintan Pharma Chem posts Q1 FY24 consolidated PAT at Rs. 9.50 Cr

The company has reported total income of Rs. 115.37 crores during the period ended June 30, 2023

Indraprastha Medical Corporation Q1 FY24 PAT up at Rs. 30.50 Cr

The company has reported total income of Rs. 310.07 crores during the period ended June 30, 2023

Briefs: Dr. Reddy's Laboratories and Aurobindo Pharma

The inspection closed with zero observations and a classification of No Action Indicated

Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride for Injection USP

The product is being launched in August 2023

Granules Pharmaceuticals successfully completes USFDA post marketing adverse drug experience inspection with zero observations

The inspection was conducted at Granules Pharmaceuticals Inc. (GPI) from July 31, 2023 to August 03, 2023

Yashoda Medicity, Indirapuram and Draeger India join hands to establish modular ICU setup

Aiming to establish a state-of-the-art healthcare facility in India that integrates the latest technologies, exceptional patient comfort, and optimal clinical outcomes